Publications by authors named "L Cristofani"
Background: Receptor activator of nuclear factor kappa-B ligand (RANKL) can directly promote tumor growth and indirectly support tumor immune evasion by altering the tumor microenvironment and immune cell responses. This study aimed to assess the prognostic significance of soluble RANKL in patients with advanced non-small cell lung cancer (NSCLC) receiving programmed cell death 1 (PD1)/programmed death-ligand 1 (PDL1) checkpoint inhibitor therapy.
Methods: Plasma RANKL levels were measured in 100 patients with advanced NSCLC without bone metastases undergoing monotherapy with PD1/PDL1 checkpoint inhibitors.
Correction: First Transcriptome Analysis of Hepatoblastoma in Brazil: Unraveling the Pivotal Role of Noncoding RNAs and Metabolic Pathways.
Biochem Genet
June 2024
Article Synopsis
- - The study focused on treatment experiences for kids with NTRK-fused tumors, looking at access to care, how they responded to treatment, side effects, and overall health outcomes.
- - Researchers reviewed data from 17 pediatric cases treated with larotrectinib, identifying six NTRK fusion subtypes and noting that 11 of 14 patients had positive tumor responses, with various levels of adverse effects reported.
- - The findings suggest that larotrectinib is effective for treating these tumors in children, but challenges still exist in ensuring consistent access to treatment, particularly in countries with limited resources like Brazil.
Article Synopsis
- * A transcriptome analysis of 14 pediatric hepatoblastoma samples revealed 1,492 genes with altered expression, highlighting important biological processes and known cancer-associated genes as well as some novel gene discoveries.
- * The study identified significant changes in gene expression linked to processes like cell differentiation and metabolism, and noted a large number of dysregulated non-coding RNAs, suggesting their potential role in hepatoblastoma biology.
We estimated the prevalence and clinical outcomes of sarcopenia among breast cancer patients. A systematic literature search was carried out for the period between July 2023 and October 2023. Studies with breast cancer patients evaluated for sarcopenia in relation to overall survival (OS), progression-free survival (PFS), relapse of disease (DFS), pathological complete response (pCR), or toxicity to chemotherapy were included.
View Article and Find Full Text PDF